Home›Telotristat Ethyl

Telotristat Ethyl

Also known as: Xermelo

Route: Oral

4 interactions on record

Telotristat Ethyl has 4 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Octreotide, Bupropion, Efavirenz. Patients taking Telotristat Ethyl should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 4
Major: 1
Moderate: 3

Major (1)

Telotristat Ethyl + Octreotide— Concurrent administration of short-acting octreotide significantly decreases systemic exposure of telotristat ethyl and …

Moderate (3)

Telotristat Ethyl + Bupropion— Telotristat ethyl may decrease the efficacy of bupropion by decreasing its systemic exposure. Monitor patient response a…
Telotristat Ethyl + Efavirenz— Telotristat ethyl may decrease the efficacy of efavirenz by decreasing its systemic exposure. Monitor patient response a…
Telotristat Ethyl + Midazolam— 7 DRUG INTERACTIONS CYP3A4 Substrates (e.g., midazolam): Efficacy of concomitant drugs may be decreased; monitor for sub…

Telotristat Ethyl + Octreotide⚠️Major

Concurrent administration of short-acting octreotide significantly decreases systemic exposure of telotristat ethyl and its active metabolite. Administer short-acting octreotide at least 30 minutes after telotristat ethyl.

Telotristat Ethyl + Bupropion🟡Moderate

Telotristat ethyl may decrease the efficacy of bupropion by decreasing its systemic exposure. Monitor patient response and consider increasing bupropion dosage if necessary.

Telotristat Ethyl + Efavirenz🟡Moderate

Telotristat ethyl may decrease the efficacy of efavirenz by decreasing its systemic exposure. Monitor patient response and consider increasing efavirenz dosage if necessary.

Telotristat Ethyl + Midazolam🟡Moderate

7 DRUG INTERACTIONS CYP3A4 Substrates (e.g., midazolam): Efficacy of concomitant drugs may be decreased; monitor for suboptimal efficacy and consider increasing the dose of the concomitant drug. ( 7.1 ) 7.1 CYP3A4 Substrates Concomitant use of Xermelo may decrease the efficacy of drugs that are CYP3A4 substrates (e.g., midazolam) by decreasing their systemic exposure.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.